ADUHELM is indicated for the treatment of Alzheimer’s disease. Treatment with ADUHELM should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials. This indication is approved under accelerated approval based on reduction in amyloid beta plaques observed in patients treated with ADUHELM. Continued approval for this indication may be contingent upon verification of clinical benefit in confirmatory trial(s).

Help your patients access ADUHELM

If you’re considering prescribing ADUHELM, the PATH program could help eligible patients access their medication.

The PATH program provides ADUHELM financial assistance* to eligible patients.

*Patient out-of-pocket cost may vary based on financial and other income considerations. This program only covers the cost of ADUHELM. Other services or fees associated with treatment are not included and patient may have out-of-pocket costs associated with the same. Other restrictions apply. Biogen reserves the right to modify or discontinue this program with respect to any patient, or in its entirety, at any time. New enrollment ends 9/1/2024; program ends 12/31/2024. Contact Biogen Support Services for Patients for full program details and Terms and Conditions.


Contact Biogen Support Services for Patients at 1-833-425-9360 Monday–Friday

Patient Registry

The Alzheimer’s Network for Treatment and Diagnostics (ALZ-NET) is a voluntary provider-enrolled patient registry that collects information on treatments for Alzheimer’s disease, including ADUHELM. Providers may obtain information about the registry at or contact